Search results for " lip"

showing 10 items of 1180 documents

COMBINATION OF ARGAN OIL AND PHOSPHOLIPIDS FOR THE DEVELOPMENT OF AN EFFECTIVE LIPOSOME-LIKE FORMULATION ABLE TO IMPROVE SKIN HYDRATION AND ALLANTOIN…

2016

Allantoin is traditionally employed in the treatment of skin ulcers and hypertrophic scars. In the present work, to improve its local deposition in the skin and deeper tissues, allantoin was incorporated in conventional liposomes and in new argan oil enriched liposomes. In both cases, obtained vesicles were unilamellar, as confirmed by cryo-TEM observation, but the addition of argan oil allowed a slight increase of the mean diameter (∼130nm versus ∼85nm). The formulations, especially those containing argan oil, favoured the allantoin accumulation in the skin, in particular in the dermis (∼8.7μg/cm(2)), and its permeation through the skin (∼33μg/cm(2)). The performances of vesicles as skin d…

3003Pig skinfood.ingredientSwineChemistry PharmaceuticalSkin AbsorptionPharmaceutical ScienceArgan oil02 engineering and technologyAdministration Cutaneous030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineAllantoinfoodDermisElastic ModulusSkin rheologymedicineAnimalsPlant OilsAllantoinSofteningPhospholipidsSkinDrug CarriersLiposomeChromatographyintegumentary systemChemistryVesicleLiposomes; Argan oil; Phospholipids; Pig skin; Turbiscan lab; Skin rheology; Skin hydrationPermeation021001 nanoscience & nanotechnologyTurbiscan labmedicine.anatomical_structureSkin hydrationArgan oilLiposomesDermatologic Agents0210 nano-technologyDrug carrierargan oil; liposomes; phospholipids; pig skin; skin hydration; skin rheology; turbiscan lab; 3003
researchProduct

Gold nanostar–polymer hybrids for siRNA delivery: Polymer design towards colloidal stability and in vitro studies on breast cancer cells

2017

To overcome the low bioavailability of siRNA (small interfering RNA) and to improve their transfection efficiency, the use of non-viral delivery carriers is today a feasible approach to transform the discovery of these incredibly potent and versatile drugs into clinical practice. Polymer-modified gold nanoconstructs (AuNCs) are currently viewed as efficient and safe intracellular delivery carriers for siRNA, as they have the possibility to conjugate the ability to stably entrap and deliver siRNAs inside cells with the advantages of gold nanoparticles, which can act as theranostic agents and radiotherapy enhancers through laser-induced hyperthermia. In this study, AuNCs were prepared by coat…

3003siRNA deliverySmall interfering RNAPolymersMetal NanoparticlesPharmaceutical ScienceGold Colloid02 engineering and technologyPolyethylene Glycol01 natural sciencesPolyethylene GlycolsGold Colloidchemistry.chemical_compoundDrug Delivery SystemsMCF-7 CellDrug StabilityCoatingRNA Small InterferingPolymerDrug Carrierchemistry.chemical_classificationDrug CarriersTumorLipoic acidGold nanostarPolymer021001 nanoscience & nanotechnologyColloidal goldMCF-7 Cells0210 nano-technologyDrug carrierHydrophobic and Hydrophilic InteractionsBreast NeoplasmHumanBiological AvailabilityReproducibility of ResultBreast NeoplasmsNanotechnologyPolyethylene glycolengineering.materialSmall InterferingTransfection010402 general chemistryCell LineHydrophobic and Hydrophilic InteractionMetal NanoparticleCell Line TumorAmphiphileHumansGene SilencingParticle SizeGold nanostarsReproducibility of ResultsGold nanostars; Lipoic acid; MCF-7; PEG; PHEA; siRNA delivery; Biological Availability; Breast Neoplasms; Cell Line; Tumor; Drug Carriers; Drug Delivery Systems; Drug Stability; Gene Silencing; Gold; Gold Colloid; Humans; Hydrophobic and Hydrophilic Interactions; MCF-7 Cells; Metal Nanoparticles; Particle Size; Polyethylene Glycols; Polymers; RNA; Small Interfering; Reproducibility of Results; Transfection; 3003PHEAPEG0104 chemical scienceschemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoengineeringRNAGoldMCF-7Drug Delivery SystemInternational Journal of Pharmaceutics
researchProduct

Dietary Intake of n-6 Fatty Acids Modulates Effect of Apolipoprotein A5 Gene on Plasma Fasting Triglycerides, Remnant Lipoprotein Concentrations, and…

2006

Background— Apolipoprotein A5 gene (APOA5) variation is associated with plasma triglycerides (TGs). However, little is known about whether dietary fat modulates this association. Methods and Results— We investigated the interaction between APOA5 gene variation and dietary fat in determining plasma fasting TGs, remnant-like particle (RLP) concentrations, and lipoprotein particle size in 1001 men and 1147 women who were Framingham Heart Study participants. Polymorphisms –1131T>C and 56C>G, representing 2 independent haplotypes, were analyzed. Significant gene–diet interactions between the –1131T>C polymorphism and polyunsaturated fatty acid (PUFA) intake were found (PG polymorphism. The –1131…

:CIENCIAS MÉDICAS ::Medicina interna [UNESCO]LipoproteinsUNESCO::CIENCIAS MÉDICASGeneticsDiet ; Fatty acids ; Genetics ; Lipids ; Lipoproteinslipids (amino acids peptides and proteins)Fatty acids:CIENCIAS MÉDICAS [UNESCO]LipidsUNESCO::CIENCIAS MÉDICAS ::Medicina internaDiet
researchProduct

A New Bloody Pulp Selection of Myrobalan (Prunus cerasifera L.): Pomological Traits, Chemical Composition, and Nutraceutical Properties

2023

A new accession of myrobalan (Prunus cerasifera L.) from Sicily (Italy) was studied for the first time for its chemical and nutraceutical properties. A description of the main morphological and pomological traits was created as a tool for characterization for consumers. For this purpose, three different extracts of fresh myrobalan fruits were subjected to different analyses, including the evaluation of total phenol (TPC), flavonoid (TFC), and anthocyanin (TAC) contents. The extracts exhibited a TPC in the range 34.52–97.63 mg gallic acid equivalent (GAE)/100 g fresh weight (FW), a TFC of 0.23–0.96 mg quercetin equivalent (QE)/100 g FW, and a TAC of 20.24–55.33 cyanidine-3-…

<i>Prunus cerasifera</i>; myrobalan; LC-MS analysis; antioxidant activity; lipase and carbohydrate hydrolyzing enzymes inhibitory effectsSettore AGR/03 - Arboricoltura Generale E Coltivazioni ArboreePrunus cerasiferaHealth (social science)LC-MS analysilipase and carbohydrate hydrolyzing enzymes inhibitory effectsantioxidant activitySettore CHIM/06 - Chimica OrganicaPlant ScienceHealth Professions (miscellaneous)MicrobiologymyrobalanFood ScienceFoods
researchProduct

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.

2022

Funder: European Commission

ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct

CLINICAL CHARACTERISTICS AND PLASMA LIPIDS IN SUBJECTS WITH FAMILIAL COMBINED HYPOLIPIDEMIA: A POOLED ANALYSIS

2013

Background. Angiopoietin-like 3 (ANGPTL3) regulates lipoprotein metabolism by modulating extracellular lipases. Loss-of function mutations in ANGPTL3 gene cause familial combined hypolipidemia (FHBL2). The mode of inheritance and hepatic and vascular consequences of FHBL2 have not been fully elucidated. To get further insights on these aspects, we re-evaluated the clinical and the biochemical characteristics of all reported cases of FHBL2. Methods and Results. One hundred fteen FHBL2 individuals carrying 13 different mutations in the ANGPTL3 gene (14 homozygotes, 8 compound heterozygotes and 93 heterozygotes) and 402 controls were considered. Carriers of 2 mutant alleles had undetectable pl…

ANGPTL3 mutations; angiopoietin-like 3; cardiovascular disease; diabetes mellitus; fatty liverSettore MED/09 - Medicina InternaCompound heterozygosityBiochemistryCohort StudiesHypobetalipoproteinemiasEndocrinologyANGPTL3cardiovascular diseaseGenotypeChildLipoproteinclinical characteristicsAged 80 and overbiologydiabetes mellituFatty liverHomozygoteLipoprotein(a)Middle AgedANGPTL3 mutationLipidsCardiovascular Diseasesdiabetes mellitusANGPTL3 Familial combined hypolipidemia LipoproteinAdultmedicine.medical_specialtyHeterozygoteANGPTL3; Familial combined hypolipidemia; clinical characteristicsAdolescentEvinacumabQD415-436Young AdultDiabetes mellitusInternal medicinemedicineHumansANGPTL3 mutationsAlleleFamilial combined hypolipidemiaAgedAngiopoietin-Like Protein 3fatty liverangiopoietin-like 3Cell Biologymedicine.diseaseEndocrinologyAngiopoietin-like ProteinsGene Expression RegulationMutationbiology.proteinPatient-Oriented and Epidemiological ResearchAngiopoietinsLipoproteinLipoprotein(a)
researchProduct

Partial substitution of fish meal with vegetable protein sources in a diet for sea bass: effects on lipogenesis

2005

Three isoproteic (49.4%) and isolipidic (17.0%) diets were prepared: A control diet FM, in which protein was derived from fish meal and two experimental diets in which 70% of the fish meal protein was substituted with wheat gluten meal (WGM) or wheat gluten meal plus soybean meal (WGMsb), respectively. The essential limiting amino acids were added to satisfy the requirements of the species (Tibaldi et al., 1996). Three hundred and fifteen sea bass (initial weight = 23.9±0. 1g )were randomly divided into nine homogenous groups. The animals were reared in a closed recirculation system at 23.9 ◦ C and were fed ad libitum twice a day for 96 days. The fish were weighed at the beginning and the e…

ATP citrate lyaseDicentrarchus labrax; Dietary Proteins; body lipid composition; adipositySoybean mealfish meal lipid composition lipid deposition sea bass vegetable proteinsBiologyGlucosephosphate DehydrogenasePlant Proteins DietaryFish mealMalate DehydrogenaseSettore BIO/10 - BiochimicaFish ProductsAnimalsSettore AGR/18 - Nutrizione E Alimentazione AnimaleDicentrarchus labraxFood scienceSea basschemistry.chemical_classificationMealadiposityGeneral VeterinaryBody WeightFatty acidGeneral MedicineLipid MetabolismAnimal Feedbody lipid compositionchemistryLiverLipogenesisATP Citrate (pro-S)-LyaseBody CompositionComposition (visual arts)BassDietary Proteins
researchProduct

Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia.

2021

Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&amp;A format. Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-r…

ATP citrate lyaseEndocrinology Diabetes and MetabolismMedicine (miscellaneous)HyperlipidemiasPharmacologyLipid-lowering therapyLipid-lowering treatmentMedicineLDL-cholesterolHumansDicarboxylic AcidsHypolipidemic AgentsLdl cholesterolNutrition and DieteticsLipid managementbusiness.industryNovel LDL-C treatment.Fatty AcidsCholesterol LDLBempedoic acidNovel LDL-C treatmentATP citrate lyaseATP citrate lyase; bempedoic acid; LDL-cholesterol; lipid-lowering treatment; novel LDL-C treatmentLipid loweringCardiology and Cardiovascular MedicinebusinessClinical evaluationBempedoic acidNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Molecular basis of the effects of argan oil on mitochondrial and peroxisomal metabolism of the fatty acids and inflammation

2012

The objective of this thesis work was to explore the molecular basis of Argan Oil (AO) effects on the mitochondrial and peroxisomal lipid metabolism and to elucidate its anti-inflammatory potential. We thus showed, initially, that the artisanal method preparation preserved the antioxidant properties of AO preventing the oxidation of the ferulic acid, by contrast to AO of commercial origin. Then, the treatment by the AO or lipopolysaccharides (LPS) of human fibroblasts, the cellular model of pseudo-neonatal adrenoleukodystrophy (P-NALD), revealed for the AO that peroxisomes proliferation is independent from the activation of the nuclear receptor PPARα and the co-activator PGC-1α. On the othe…

Acide féruliqueLPSACADsPGC-1αArganPPARαTNFα[ SDV.SA ] Life Sciences [q-bio]/Agricultural sciencesInflammation[SDV.SA] Life Sciences [q-bio]/Agricultural sciencesIL-6GluconeogenesisP-NALDFerulic acidMitochondrieLipid MetabolismFatty acidMétabolisme lipidiqueAntioxydantMitochondriaAcide grasLiverΒ-oxidationNéoglucogenèseAntioxidantACOX1PeroxysomeFoieIL10Β-oxydation
researchProduct

SOLID LIPID NANOPARTICLES FOR APPLICATIONS IN GENE THERAPY: A REVIEW OF THE STATE OF THE ART

2010

Importance of the field. Gene therapy represents a new paradigm in the prevention and treatment of many inherited and acquired diseases, including genetic disorders, such as cystic fibrosis, haemophilia and many somatic diseases, such as tumours, neurodegenerative diseases and viral infections, such as AIDS. Areas covered in this review. Among a large array of non-viral transfection agents used for in-vitro applications, cationic SLNs are the topic of this review, being recently proposed as an alternative carrier for DNA delivery, due to many technological advantages such as large-scale production from substances generally recognized as safe, good storage stability and possibility of steam …

Acquired diseasesGenetic enhancementGenetic VectorsPharmaceutical ScienceGene deliveryBiologyBioinformaticsCystic fibrosisGenetic therapyGENE THERAPY SOLID LIPID NANOPARTICLESSolid lipid nanoparticlemedicinegene deliverybusiness.industrynon-viral vectors Read More: http://informahealthcare.com/doi/abs/10.1517/17425240903362410DNAGenetic Therapymedicine.diseasegene therapyLipidsBiotechnologySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoMicroscopy Electron ScanningNanoparticlesbusinesscationic solid lipid nanoparticles
researchProduct